Companies: 49,246 Total Market Cap: 132441797263938.02

Avadel Pharmaceuticals plc

NASDAQ: AVDL

Healthcare Drug Manufacturers - Specialty & Generic

Rank #9900

Market Cap 899.67 M

Volume 152,152

Price 9.30

Change (%) 0.53%

Country or region

Ireland

Avadel Pharmaceuticals plc's latest marketcap:

899.67 M

As of 05/20/2025, Avadel Pharmaceuticals plc's market capitalization has reached $899.67 M. According to our data, Avadel Pharmaceuticals plc is the 9900th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap	899.67 M
Revenue (ttm)	194.45 M
Net Income (ttm)	-26,410,000
Shares Out	96.74 M
EPS (ttm)	-0.27
Forward PE	26.49
Ex-Dividend Date	n/a
Earnings Date	05/07/2025

Market Cap Chart

Data Updated: 05/20/2025

Avadel Pharmaceuticals plc's yearly market capitalization.

Avadel Pharmaceuticals plc has seen its market value grow from $70.50 M to $899.67 M since 2002, representing a total increase of 1,176.13% and an annual compound growth rate (CAGR) of 12.05%.

Date	Market Cap	Change (%)
05/20/2025	$899.67 M	-10.31%
12/31/2024	$1.01 B	-20.13%
12/29/2023	$1.27 B	186.71%
12/30/2022	$442.30 M	-6.63%
12/31/2021	$473.70 M	21.68%
12/31/2020	$389.30 M	37.71%
12/31/2019	$282.70 M	196.02%
12/31/2018	$95.50 M	-70.71%
12/29/2017	$326.10 M	-23.9%
12/30/2016	$428.50 M	-12.68%
12/31/2015	$490.70 M	11.85%
12/31/2014	$438.70 M	118.37%
12/31/2013	$200.90 M	165.74%
12/31/2012	$75.60 M	-41.12%
12/30/2011	$128.40 M	-22.88%
12/31/2010	$166.50 M	-7.04%
12/31/2009	$179.10 M	89.93%
12/31/2008	$94.30 M	-60.61%
12/31/2007	$239.40 M	-66.28%
12/29/2006	$710 M	72.88%
12/30/2005	$410.70 M	-1.49%
12/31/2004	$416.90 M	-3.92%
12/31/2003	$433.90 M	515.46%
12/31/2002	$70.50 M

Company Profile

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc is a biopharmaceutical company based in the United States, focused on innovative therapies for sleep disorders and other medical conditions.

Key Product Candidate

LUMRYZ – A sodium oxybate formulation currently in Phase 3 clinical trials for treating:

Cataplexy
Excessive daytime sleepiness (EDS)

The therapy is being evaluated for patients aged seven and older with narcolepsy.

Company Background

Formerly known as Flamel Technologies SA, the company rebranded as Avadel Pharmaceuticals plc in January 2017. Founded in 2015, its headquarters are located in Dublin 2, Ireland.

Frequently Asked Questions

As of 05/20/2025, Avadel Pharmaceuticals plc (including the parent company, if applicable) has an estimated market capitalization of $899.67 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Avadel Pharmaceuticals plc global market capitalization ranking is approximately 9900 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region	Ireland
Founded	2015
IPO Date	06/07/1996
Employees	188
CEO	Gregory Divis
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Address	10 Earlsfort Terrace Dublin 2, D02 T380 Ireland
Website	https://www.avadel.com